News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
231,257 Results
Type
Article (5084)
Company Profile (23)
Press Release (226150)
Multimedia
Podcasts (2)
Webinars (4)
Section
Business (82245)
Career Advice (462)
Deals (15054)
Drug Delivery (8)
Drug Development (19073)
Employer Resources (30)
FDA (3681)
Job Trends (3911)
News (120176)
Policy (7511)
Tag
Academia (293)
Accelerated approval (6)
Adcomms (3)
Allergies (12)
Alliances (14809)
ALS (38)
Alzheimer's disease (290)
Antibody-drug conjugate (ADC) (36)
Approvals (3772)
Artificial intelligence (74)
Autoimmune disease (24)
Automation (5)
Bankruptcy (97)
Best Places to Work (2866)
Biosimilars (31)
Biotechnology (23)
Bladder cancer (30)
Brain cancer (7)
Breast cancer (96)
Cancer (843)
Cardiovascular disease (58)
Career advice (394)
Career pathing (3)
CAR-T (63)
CDC (2)
Cell therapy (158)
Cervical cancer (4)
Clinical research (16613)
Collaboration (323)
Compensation (345)
Complete response letters (6)
COVID-19 (311)
CRISPR (13)
C-suite (299)
Cystic fibrosis (27)
Data (1248)
Denatured (1)
Depression (21)
Diabetes (70)
Diagnostics (2101)
Digital health (6)
Diversity, equity & inclusion (13)
Drug discovery (30)
Drug pricing (13)
Drug shortages (2)
Duchenne muscular dystrophy (34)
Earnings (42618)
Editorial (5)
Employer branding (6)
Employer resources (32)
Events (38962)
Executive appointments (414)
FDA (4376)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (1)
Frontotemporal dementia (8)
Funding (318)
Gene editing (24)
Generative AI (4)
Gene therapy (97)
GLP-1 (142)
Government (421)
Guidances (196)
Healthcare (5043)
HIV (10)
Huntington's disease (4)
IgA nephropathy (11)
Immunology and inflammation (37)
Immuno-oncology (6)
Indications (14)
Infectious disease (335)
Inflammatory bowel disease (35)
Inflation Reduction Act (3)
Influenza (6)
Intellectual property (30)
Interviews (53)
IPO (7876)
IRA (3)
Job creations (1123)
Job search strategy (361)
Kidney cancer (10)
Labor market (9)
Layoffs (106)
Leadership (5)
Legal (2337)
Liver cancer (21)
Longevity (2)
Lung cancer (86)
Lymphoma (68)
Machine learning (3)
Management (10)
Manufacturing (124)
MASH (49)
Medical device (3913)
Medtech (3921)
Mergers & acquisitions (7558)
Metabolic disorders (199)
Multiple sclerosis (16)
NASH (6)
Neurodegenerative disease (49)
Neuropsychiatric disorders (10)
Neuroscience (518)
NextGen: Class of 2025 (1675)
Non-profit (730)
Now hiring (6)
Obesity (78)
Opinion (31)
Ovarian cancer (25)
Pain (25)
Pancreatic cancer (35)
Parkinson's disease (47)
Partnered (5)
Patents (48)
Patient recruitment (89)
Peanut (5)
People (25118)
Pharmaceutical (6)
Pharmacy benefit managers (2)
Phase I (4974)
Phase II (7195)
Phase III (5762)
Pipeline (1708)
Policy (16)
Postmarket research (625)
Preclinical (1944)
Press Release (66)
Prostate cancer (53)
Psychedelics (3)
Radiopharmaceuticals (107)
Rare diseases (157)
Real estate (1886)
Recruiting (8)
Regulatory (5469)
Reports (17)
Research institute (308)
Resumes & cover letters (69)
Rett syndrome (16)
RSV (2)
Schizophrenia (46)
Series A (52)
Series B (51)
Sickle cell disease (10)
Special edition (1)
Spinal muscular atrophy (30)
Sponsored (5)
Startups (1017)
Stomach cancer (1)
Supply chain (12)
Tariffs (7)
The Weekly (1)
Vaccines (77)
Venture capital (8)
Weight loss (29)
Women's health (4)
Date
Today (4)
Last 7 days (44)
Last 30 days (461)
Last 365 days (9023)
2026 (9)
2025 (9037)
2024 (11031)
2023 (13197)
2022 (18662)
2021 (19678)
2020 (18240)
2019 (13205)
2018 (10207)
2017 (10003)
2016 (9162)
2015 (12119)
2014 (9588)
2013 (7708)
2012 (8330)
2011 (8796)
2010 (8635)
Location
Africa (186)
Alabama (17)
Alaska (2)
Arizona (73)
Arkansas (1)
Asia (11743)
Australia (1677)
California (3345)
Canada (1102)
China (155)
Colorado (134)
Connecticut (156)
Delaware (68)
Europe (25389)
Florida (511)
Georgia (62)
Idaho (24)
Illinois (152)
India (14)
Indiana (99)
Iowa (9)
Japan (153)
Kansas (36)
Kentucky (17)
Louisiana (8)
Maine (50)
Maryland (339)
Massachusetts (2653)
Michigan (100)
Minnesota (194)
Mississippi (1)
Missouri (30)
Montana (16)
Nebraska (12)
Nevada (43)
New Hampshire (16)
New Jersey (978)
New Mexico (5)
New York (774)
North Carolina (462)
North Dakota (4)
Northern California (1730)
Ohio (109)
Oklahoma (5)
Oregon (5)
Pennsylvania (571)
Puerto Rico (1)
Rhode Island (18)
South America (276)
South Carolina (16)
Southern California (1232)
Tennessee (59)
Texas (447)
United States (11719)
Utah (104)
Virginia (80)
Washington D.C. (17)
Washington State (280)
West Virginia (2)
Wisconsin (49)
Wyoming (1)
231,257 Results for "omeros corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros’ Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)
December 2, 2025
·
7 min read
Press Releases
Omeros Corporation Reports Third Quarter 2025 Financial Results
November 14, 2025
·
20 min read
Rare diseases
Novo Offers up to $2.1B for Omeros’ Complement Drug To Expand Rare Disease Work
Novo Nordisk strikes another deal, this time with Omeros, amid a broader pipeline restructuring that recently claimed its cell therapy work.
October 15, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025
November 11, 2025
·
2 min read
Press Releases
Omeros Announces New Date for YARTEMLEA® Approval Conference Call
December 29, 2025
·
7 min read
Press Releases
FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA
December 25, 2025
·
17 min read
Press Releases
Omeros Corporation Reports Second Quarter 2025 Financial Results
August 15, 2025
·
20 min read
Press Releases
Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025
August 12, 2025
·
2 min read
Press Releases
Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering
July 28, 2025
·
4 min read
Press Releases
Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros’ clinical-stage MASP-3 inhibitor zaltenibart (OMS906)
October 16, 2025
·
8 min read
1 of 23,126
Next
